- Previous Close
2.9000 - Open
2.8600 - Bid --
- Ask --
- Day's Range
2.5800 - 2.9000 - 52 Week Range
2.5800 - 13.6000 - Volume
4,220 - Avg. Volume
993 - Market Cap (intraday)
36.769M - Beta (5Y Monthly) 0.21
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.10
Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.
www.aelisfarma.comRecent News: AELIS.PA
View MorePerformance Overview: AELIS.PA
Trailing total returns as of 11/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AELIS.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AELIS.PA
View MoreValuation Measures
Market Cap
39.49M
Enterprise Value
31.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.07
Price/Book (mrq)
3.97
Enterprise Value/Revenue
4.24
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-65.19%
Return on Assets (ttm)
-17.67%
Return on Equity (ttm)
-51.97%
Revenue (ttm)
10.78M
Net Income Avi to Common (ttm)
-7.03M
Diluted EPS (ttm)
-0.5300
Balance Sheet and Cash Flow
Total Cash (mrq)
12.59M
Total Debt/Equity (mrq)
51.13%
Levered Free Cash Flow (ttm)
-10.75M